Aluminum compounds for use in therapeutics and vaccines

Patent metadata

Field	Value
Publication number	US-2020360511-A1
Application number	US-202016734866-A
Country	US
Kind code	A1
Filing date	Jan 6, 2020
Priority date	Apr 18, 2012
Publication date	Nov 19, 2020
Grant date	—

Abstract

The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.

First claim

What is claimed is:

1 .- 26 . (canceled)

27 . An aqueous pharmaceutical composition or vaccine, comprising a protein and an aluminum salt, and wherein said aqueous pharmaceutical composition comprises less than 3 ppb heavy metal copper (Cu) based on the weight of the composition.

28 . The aqueous pharmaceutical composition or vaccine according to claim 27 , comprising less than 2.5 ppb heavy metal Cu based on the weight of the composition.

29 . The aqueous pharmaceutical composition or vaccine according to claim 27 , comprising less than 1.25 ppb heavy metal Cu based on the weight of the composition (p. 7, ln. 23).

30 . The aqueous pharmaceutical composition or vaccine according to claim 27 , comprising less than 350 ppb heavy metal based on the weight of the composition, wherein said heavy metal is selected from the group consisting of nickel (Ni), tungsten (W), cobalt (Co), osmium (Os), ruthenium (Ru), cadmium (Cd), silver (Ag), iron (Fe), vanadium (V), chromium (Cr), lead (Pb), rubidium (Rb), and molybdenum (Mo).

31 . The aqueous pharmaceutical composition or vaccine according to claim 27 , comprising less than 40 ppb nickel (Ni) based on the weight of the aqueous composition.

32 . The aqueous pharmaceutical composition or vaccine according to claim 27 , comprising between 5 ppb and 250 ppb iron (Fe) based on the weight of the aqueous composition.

33 . The aqueous pharmaceutical composition or vaccine according to claim 30 , wherein the heavy metal is present in ionic form.

34 . The aqueous pharmaceutical composition or vaccine according to claim 27 , wherein the presence of the heavy metal affects the storage stability of the protein of the composition.

35 . The aqueous pharmaceutical composition or vaccine according to claim 27 , which can be stored at temperatures higher than 20° C. for at least 1 month without protein degradation.

36 . The aqueous pharmaceutical composition or vaccine according to claim 27 , which can be stored at temperatures higher than 20° C. for at least 20 months without protein degradation.

37 . The aqueous pharmaceutical composition or vaccine according to claim 27 , wherein the protein is an immunogenic viral protein or immunogenic bacterial protein or an immunogenic part of such protein.

38 . The aqueous pharmaceutical composition or vaccine according to claim 27 , wherein said vaccine is directed against infection with Bacillus anthracis, Corynebacterium diphtheriae, Clostridium tetani, Pseudomonas aeruginosa, Staphylococcus aureus or Staphylococcus epidermidis, Haemophilus influenzae type B (Hib), Rickettsia , Meningococcus, polio virus, hepatitis A virus, hepatitis B virus, human papillomavirus, influenza virus, Japanese encephalitis virus, rotavirus, yellow fever virus, varicella zoster virus, or a combination thereof, such as DTP.

39 . The aqueous pharmaceutical composition or vaccine according to claim 27 , wherein said vaccine is the Japanese encephalitis vaccine.

40 . The aqueous pharmaceutical composition or vaccine according to claim 27 , comprising between 5 μg/ml and 50 mg/ml aluminum.

41 . The aqueous pharmaceutical composition or vaccine according to claim 27 , wherein the aluminum salt is aluminum hydroxide (Al(OH) 3 ) or aluminum phosphate (AlPO 4 ).

42 . The aqueous pharmaceutical composition or vaccine according to claim 27 , further comprising a reactive compound selected from the group consisting of a redox active compound, a radical building compound, a stabilizing compound, and a combination thereof.

43 . The aqueous pharmaceutical composition or vaccine according to claim 27 , further comprising a reactive compound selected from the group consisting of formaldehyde, ethanol, chloroform, trichloroethylene, acetone, polyethylene glycol tert-octylphenyl ether, deoxycholate, diethyl pyrocarbonate, sulphite, sodium metabisulfite (Na 2 S 2 O 5 ), beta-proprio-lactone, polysorbate optionally Polysorbate 20 or Polysorbate 80, O 2 , phenol, pluronic type copolymers, and a combination of thereof.

44 . The aqueous pharmaceutical composition or vaccine according to claim 27 , further comprising sulphite.

45 . An aqueous pharmaceutical composition or vaccine comprising a protein and an aluminum salt, wherein said aqueous pharmaceutical composition comprises less than 350 ppb heavy metal based on the weight of the composition, wherein the heavy metal is selected from copper (Cu), nickel (Ni), tungsten (W), cobalt (Co), osmium (Os), ruthenium (Ru), cadmium (Cd), silver (Ag), iron (Fe), vanadium (V), chromium (Cr), lead (Pb), rubidium (Rb), and molybdenum (Mo).

46 . An aqueous pharmaceutical composition or vaccine comprising a protein and an aluminum salt obtainable by the method comprising:
a) preparing an aluminum salt precipitate, b) determining the level of copper (Cu) in the aluminum salt precipitate, and c) combining said aluminum salt precipitate, the protein, and water to produce said aqueous composition, wherein the aluminum salt provides an aqueous composition having less than 3 ppb Cu based on the weight of the composition.

Assignees

• Valneva Austria Gmbh

Inventors

• Schlegl Robert
• Möhlen Michael
• Heindl-Wruss Jürgen
• Weber Michael

Classifications

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K39/39 Primary

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61K39/12

  Viral antigens · CPC title

• A61K2039/525

  Virus · CPC title

• A61K2039/5252

  inactivated (killed) · CPC title